Additionally, recent studies have shown that baricitinib, a JAK inhibitor, can ameliorate the destruction of alveolar cells in the SG of SS patients by reducing IFN-γ-induced CXCL10 expression and CXCL10-dependent immune cells infiltration in the SGECs (170). Here, CXCL10 is linked to synovial sarcoma.